The Drummond Lecture 2026 Professor Alessio Ciulli FRS FRSE FRSC
In this lecture, Professor Ciulli will explore how protein degraders, such as PROTACs and molecular glues, are transforming pharmacology from inhibition to targeted protein removal. Drawing on cutting-edge research from his laboratory, he will discuss the molecular mechanisms underpinning degrader function, recent advances in structural and chemical biology, and their application to challenging diseases including cancer and neurodegeneration. The talk will also highlight emerging collaborations between academia and industry that are driving the next generation of therapeutic innovation.
When: Friday 15th May 2026
Where: Peston Lecture Theatre, Graduate Centre, Mile End Campus
Our laboratory at the Centre for Targeted Protein Degradation (CeTPD) reveals molecular information on protein interactions and ubiquitination complexes and mechanisms to design novel therapeutic concepts. Protein degraders, also known as PROTACs (PROteolysis-TArgeting Chimeras) and molecular glues, recruit a target protein to a ubiquitin E3 ligase for targeted protein degradation. Formation of a stable ternary complex between the degrader, the E3 ligase and the target is a critical step that leads to productive tagging of the target protein by ubiquitination, and subsequent proteasomal degradation. Our research has illuminated fundamental structural and biophysical insights into molecular recognition and mechanism of action of protein degraders, that have guided the design and optimization of novel small molecules for hard-to-target proteins. I will be reflecting on the evolution of the TPD field, from early design principles to today’s landscape of PROTACs and molecular glues. Latest advances from the Lab in mechanistic understanding and chemical structural biology of degraders ternary complexes will be presented. I will also highlight collaborative academic-industry consortia tackling grand challenges with undruggable targets in pediatric cancers and neurodegenerative diseases, charting the next-generation of proximity-based therapeutics.
Alessio Ciulli is renowned for his pioneering work in targeted protein degradation (TPD), a cutting-edge approach in drug discovery that harnesses the cell's natural disposal machinery to eliminate disease-causing proteins. This new modality witnesses over 50 drugs currently in clinical trials. His research has significantly advanced our understanding of how to develop more effective therapies through the design of molecules known as PROTACs (Proteolysis Targeting Chimeras) and molecular glues. He has authored high-impact publications, co-founded biotech ventures, partnered with the pharmaceutical industry, and has attracted international recognition through prestigious awards—including his recent election as a Fellow of the Royal Society. His leadership at Dundee’s Centre for Targeted Protein Degradation underscores his influential role in translating basic science into innovative therapeutic solutions.